INFILTRATING/INVASIVE DUCTAL CARCINOMA WITH HER2 ENRICHED BREAST CANCER – CASE REPORT
Archana Lahoti* and Dr. Pankaj K. Barman
Background: Invasive/Infiltrating Ductal Carcinoma (IDC) is a cancer that grows in the milk ducts and invades the fibrous/fatty tissues of the breast. HER2 enriched cancer is cancer with Hormone Receptors(HR) negative and Human Epidermal Growth Factor Receptor 2 (HER2) positive. HER2 is thought to occur in 20 to 30 percent of breast cancer tumours. Case presentation: A 55 year old post menopausal female presented with complaints of lump in the right breast since 2 weeks. No family history of hereditary breast ovary cancer syndrome (HBOC) were found. On evaluation with Ultrasound of the breast and Mammogram, 4 cm mass was found in the right breast. On Fine needle aspiration cytology (FNAC), it was confirmed to be IDC. She underwent Modified radical mastectomy (MRM) and histopathological examination confirmed it to be a pathological state 2A. HR was negative and HER2 was positive. Conclusion: Managing HER2+ is a challenging treatment because of its inherent aggressive nature. It is important to investigate for any metastatic disease at the time of onset is important. Appropriate anti HER2 therapies along with chemotherapy in both adjuvant and metastatic settings markedly increases the overall survival.
Keywords: IDC, HER2, postmenopausal, HBOC, mastectomy.
[Full Text Article]